mol42
20 Mar 2018
Re: Hardman Note 200318 oops didn't realise co released an rns this morning - not in here mind no one seems to have noticed on here - or perhaps no one has commented is probably more correct which seems a bit strange as it provides a useful summarynever mindmol
mol42
20 Mar 2018
Hardman Note 200318 fyi[link]
d gaser
16 Mar 2018
OXB PRELIMINARY RESULTS show good growth Yesterdays results look good, it's just a pity they couldn't make that maiden profit. At least OXB income is moving in the right direction, and costs seem to be under control ,but that will change next year ,as R/D will climb again as the Phase I/II clinical study for OXB-102 Parkinson's disease program moves forward .I have one question asI'm not quite sure what they mean by Partnering discussions are ongoing for OXB's in-house priority development programmes, with a planned spin-out legal structure to be established for ocular products, are they planning to start another limited company, and if so ,who will own it and control it ?BE HAPPYDAVE t Oxford Biomedica15 Mar 2018 07
19Oxford Biomedica PLCRNS Number : 8065HOxford Biomedica PLC15 March 2018 OXFORD BIOMEDICA PLCPRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2017 Oxford, UK - 15 March 2018: Oxford BioMedica plc ("OXB" or "the Group"; LSE: OXB), a leading gene and cell therapy group, today announces preliminary results for the 12 months ended 31 December 2017 and a post-period update. FINANCIAL HIGHLIGHTS (INCLUDING POST PERIOD END)- Gross Income1 increased by 28% to £39.4 million (2016: £30.8 million)- Operating expenses excluding depreciation and amortisation and share based payments decreased by 12% to £22.9 million (2016: £26.1 million)- EBITDA loss significantly reduced to £1.9 million (2016: £7.1 million)- EBIDA (EBITDA adjusted by the R&D tax credit) profit of £0.8 million (2016: £3.4 million loss)- Operating loss for the period reduced 50% to £5.7 million (2016: £11.3 million)- Cash outflow before financing activities reduced by £9.2 million to an inflow of £1.0 million (2016: £8.3 million outflow)- Capital expenditure reduced to £2 million (2016: £6.4 million)- Debt refinanced on significantly improved terms with $55 million Oaktree Capital facility- A charge of £3.9 million (2016: Nil) was incurred upon the termination of the Oberland loan facility- Cash at 31 December 2017 of £14.3 million2 (2016: £15.3 million)- Successful £20.5 million (gross) equity Placing to fund further bioprocessing capacity to service anticipated increased demand(1) Gross Income is the aggregate of revenue (£37.6 million) and other operating income (£1.8 million) (2016: £27.8 million and £3.0 million respectively)(2) Includes $5m ring fenced under Oaktree agreement OPERATIONAL HIGHLIGHTSLeading LentiVector® delivery platform for gene and cell therapy partnerships- Major commercial supply agreement signed with Novartis for the lentiviral vector to produce CTL019 (tisagenlecleucel, brand name Kymriah™
and additional CAR-T products; over $100 million revenue potential over three years- $105 million collaboration and licence agreement completed with Bioverativ to access OXB's LentiVector® platform and manufacturing technologies for haemophilia gene therapies- Lentiviral vector demand is increasing and the Group is in several discussions regarding a range of additional collaborations Novartis' product Kymriah™- First ever LentiVector-Enabled™ product approval for the Novartis product Kymriah™ (tisagenlecleucel) in children and young adults with r/r B-cell acute lymphoblastic leukaemia (ALL) in the US- Kymriah™ sBLA submitted in the USA by Novartis in r/r diffuse large B-cell lymphoma (DLBCL) in adults; product undergoing expedited review under breakthrough designation- CTL019 European Marketing Authorisation (EMA) Application filed by Novartis for r/r B-cell ALL in children and young adults and for r/r DLBCL in adults- Primary analysis of results from the pivotal JULIET trial demonstrating that Kymriah™ (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer- US FDA Priority Review for Kymriah™ for adults with r/r DLBCL and EMA accelerated assessment for chil
batman37
13 Mar 2018
Re: massive potential! Correction oh yeah, forgot about the share placing! A few more £100m deals would be great!!
d gaser
13 Mar 2018
Re: Expansion Placing of £20.50m - dg Hi Mole 42 it's been awhile since we last spoke .As you know Mole I have all ways supported OXB as a company ,and have all ways defended its technology, I must admit though ,that over the years there have been a few challenging times, but for some reason it's product stood out above the rest for me , and new one day it would come good, and it has . I like many others here could see a good future for OXB, and for my investment, so thanks Mole for your kind words, lets hope OXB continues to prove it's doubters wrong .BE HAPPYDAVE
d gaser
13 Mar 2018
Re: Expansion Placing of £20.50m - dg Hi Mole 42 it's been awhile since we last spoke .As you know OXB I have all ways been a supporter of this technology and OXB inarticulate, over the years there have been quite a few challenging times, but for some reason it's product stood out above the rest, so I just new it would come good one day , just as many others have , and I like many others ,I could see a good future for the company eventually and for my investment, so thanks Mole for your kind words, lets hope OXB continues to prove it's doubters wrong .BE HAPPYDAVE
John of Groats
12 Mar 2018
Re: massive potential! Correction I underestimated the market cap as well!After the recent placing, the total voting rights will be 3283,687,286 giving a market cap of £423.6m at 12.9p per share.
John of Groats
12 Mar 2018
Re: massive potential! Batman,You have underestimated the market cap - it is £401m, not £350m - though I do agree with you that OXB has huge potential. As at the 1st of March, the total number of voting rights in Oxford BioMedica plc was 3,109,340,469. At 12.9p per share, that equates to £401.1m.
batman37
12 Mar 2018
massive potential! Market cap of £350m and just 2 deals potentially worth £200m+! No brainer!
mol42
09 Mar 2018
Expansion Placing of £20.50m - dg I can only say well done Dave with your optimism and support of this company over many many years here!be happy! unfortunately in and out many years ago nowbwmol
warmfront
09 Mar 2018
Re: Exspansion Placing of £20.50m .Plus update Fantastic news ; very positive on future manufacturing deals and in-house “ The Company expects OXB-102 (Parkinson's disease) to advance into clinical development in H1 2018. The Board expects to spin out / out-license at least one of the Group's in-house product candidates before the end of 2018”
Chicken Lips
09 Mar 2018
Re: Exspansion Placing of £20.50m .Plu... Can we get our hands on the placing as PI's or is this institutional (Woodfords) only?
d gaser
09 Mar 2018
Exspansion Placing of £20.50m .Plus update Well I'm not surprised at this placing ,and for once ,I'm quite pleased a placing is to be made ,This placing will enable OXB to continue it's accelerated growth over the next few years, with confidence. The future is ours at last, I just wish they could have purchased the facility rather than lease it .Be HappyDave ---------- --------The PlacingThe Company is proposing to raise approximately £20.5 million through the issue of up to 174,346,817 new ordinary shares at a price of 11.75 pence per Placing Share.The Placing is being conducted through an accelerated bookbuild process (the "Bookbuild" which will commence immediately following this announcement. Peel Hunt and WG Partners are acting as joint bookrunners in respect of the Placing.The timing of the closing of the Bookbuild and allocations are at the discretion of the Joint Bookrunners, in consultation with the Company, and will be decided at the close of the Bookbuild. Details of the outcome of the Bookbuild will be announced as soon as practicable after close of the Bookbuild.The Placing is not underwritten. The Placing Shares are not being made available to the public and none of the Placing Shares are being offered or sold in any jurisdiction where it would be unlawful to do so.The Placing is subject to the terms and conditions set out in the appendix (the "Appendix" to this announcement (which forms part of this announcement, such announcement and the Appendix together being, this "Announcement".The Placing is conditional upon, inter alia, the placing agreement entered into between the Company, Peel Hunt and WG Partners becoming unconditional in accordance with its terms and not having been terminated prior to Admission.Application has been made by the Company to the UK Listing Authority and the London Stock Exchange for up to 174,346,817 ordinary shares of 1 pence each in the Company to be admitted to the premium listing segment of the Official List of the UK Listing Authority and to be traded on the Main Market of the London Stock Exchange. The shares will be issued fully paid and will rank pari passu in all respects with the existing issued ordinary shares of 1 pence each of the Company. It is expected that admission of the shares will become effective at 8.00 a.m. on 14 March 2018, and that dealings will commence at that time.Background to the PlacingThe growing multi-billion dollar gene and cell therapy market has seen three therapies approved in the last six months, including Novartis' Kymriah, with Oxford BioMedica having the potential to receive in excess of $100 million over the next three years for supply of vector to Novartis in relation to Kymriah. There are potentially seven more therapies to be approved in the next few years.Oxford BioMedica is the first and only commercial supplier of lentiviral vectors to the gene and cell therapy market. The Company estimates that the lentiviral vector bioprocessing market was worth approximately $200 million in 2017 and is expected to grow at a 15.4 per cent. compound annual growth rate from $158 million in 2015 to $800 million by 2026. These estimates exclude milestones and royalties from partnerships which may be earned by companies operating in this space.In recent months Oxford BioMedica has been experiencing a step change in business development enquiries for its expertise across the LentiVector™ enabled platform and Oxford BioMedica has a strong IP position, know-how and expertise across that platform. The Company has successfully developed a new 200 litre manufacturing process with significant productivity improvements to address current and future demand across the main indications. Oxford BioMedica believes a new affordable full service site will meet expected long-term demand, create dual source manufacturing for partners and significantly increase capacity to a level competitive with other market participants.The Placing will provide funds to exploit the current mark
warmfront
28 Feb 2018
Worth a read RNS [link] Sounds incredibly hopeful 😊
Chicken Lips
16 Feb 2018
Todays Times Business 16 Feb 2018 An Oxford University spin-off that specialises in gene therapy applications has won a $100 million contract from Bioverativ, an American company specialising in treatments for haemophilia.Shares in Oxford Biomedica rose 11.7 per cent to 12p after it announced the deal, under which it will receive $5 million immediately and milestone payments worth up to $100 million.It is the second major deal in seven months for the company, which was spun off from Oxford University in 1995, early in the gene therapy revolution. It floated on the Alternative Investment Market in 1996, moving to the official list of the London Stock Exchange in 2001.Last July it signed a three-year deal that could be worth more than $100 million with the Swiss drugmaker Novartis to supply material for a new treatment for leukaemia.In both deals Oxford Biomedica will supply lentivectors, which are used to insert genes into human cells. Oxford Biomedica is also in line to receive royalties on sales of the company’s haemophilia products.Analysts at Peel Hunt said yesterday’s deal cemented their view that Oxford Biomedica’s technology was “at the forefront of the gene and cell therapy revolution”.[link]
